Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

PYC Therapeutics advances VP-001 for retinitis pigmentosa, securing FDA guidance for its upcoming registrational trial design and study parameters. Clinical-stage biotechnology company PYC ...